- Conditions
- Primary Sjögren's Syndrome
- Interventions
- CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 187
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
- Interventions
- Allogeneic NK Cells
- Drug
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 31
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
- Interventions
- selenomethionine, placebo, cisplatin, radiation therapy, quality-of-life assessment
- Dietary Supplement · Other · Drug + 2 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Xerostomia
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 4 Years to 100 Years
- Enrollment
- 1,150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sjogren's Syndrome
- Interventions
- Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Sjogren's Syndrome
- Interventions
- Dazodalibep, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 37
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more
- Conditions
- Dry Mouth
- Interventions
- Pilocarpine
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Dry Eye Syndromes, Sjogren's Syndrome
- Interventions
- TrueTear Intranasal Tear Neurostimulator
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 114 participants
- Timeline
- 1995 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Oral Health Related Quality of Life (OHRQoL)
- Interventions
- Botanical A, Botanical B, Vehicle (Placebo solution)
- Dietary Supplement
- Lead sponsor
- Access Business Group
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
- Interventions
- AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo, AAV2-hAQP1 Concentration 3, AAV2-hAQP1 Concentration 4
- Genetic · Other
- Lead sponsor
- MeiraGTx, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • Miami, Florida + 14 more
- Conditions
- Dental Caries
- Interventions
- silver diamine fluoride, 38%, Sodium fluoride gel, 5000 PPM
- Device
- Lead sponsor
- Texas A & M University Baylor College Of Dentistry
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sjögren's Syndrome
- Interventions
- Deucravacitinib, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 28
- States / cities
- Fullerton, California • La Palma, California • San Francisco, California + 25 more
- Conditions
- Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
- Drug · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Xerostomia, Hyperthyroidism, Thyroid Cancer
- Interventions
- Radioiodine
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 3 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Xerostomia
- Interventions
- Crest Whitening Emulsions
- Device
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neonatal Lupus, Systemic Lupus Erythematosus, Sjogren's Syndrome, Congenital Heart Block
- Interventions
- No intervention; observational
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mutans Streptococci, Xerostomia
- Interventions
- Xylitol disk
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sjögren's Disease
- Interventions
- DDY391, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 6 more
- Conditions
- Dry Eye, Sjogren's Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Systemic Lupus Erthematosus, Sjogren's Syndrome
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dry Mouth Associated With Sjogren's Syndrome, Xerostomia
- Interventions
- Placebo, 552-02
- Drug
- Lead sponsor
- Parion Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 15
- States / cities
- Trumbull, Connecticut • Gainesville, Florida • Indianapolis, Indiana + 12 more
- Conditions
- Sjögren's Syndrome (SS)
- Interventions
- Dazodalibep, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 41
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more